In February 2015, Sosei acquired 100% of Heptares’ share capital for $180 million in cash consideration and up to $220 million contingent upon the successful progression of the company’s pipeline and platform.
MVM sold the Vascular Pathways Group of Companies (Vascular Pathways, Inc. and Vascular Pathways Europe, Ltd.) to C.R. Bard on July 1, 2015. The transaction provides C.R. Bard with a best-in-class portfolio of peripheral vascular access technologies.